Trial Profile
Phase 1 study of ACE910 in healthy volunteers and hemophilia A patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 05 Jun 2020 Results (n=389) of a population pharmacokinetics and exploratory exposure analysis from six clinical studies: HAVEN1, HAVEN2, HAVEN3, HAVEN4, JapicCTI-121934 and JapicCTI-132195 published in the Clinical Pharmacokinetics
- 26 May 2016 Results (n=18) published in the New England Journal of Medicine
- 26 May 2016 Results of 18 patients with haemophilia A were published in a Chugai Pharmaceutical media release.